Recent developments in the Trump administration, including the resignation of FDA Commissioner Marty Makary, have elevated Deputy Commissioner for Food Kyle Diamantas to acting commissioner, positioning him as the leading candidate in trader assessments for a formal announcement. His prior role overseeing the Human Foods Program and connections within the administration contribute to the market's implied probability favoring his selection for the permanent post. Other potential nominees, including former officials and policy figures, trail significantly, reflecting limited recent signals of alternative appointments. The low odds on no announcement by year-end underscore expectations of a timely decision amid ongoing agency leadership transitions and policy priorities.
基於Polymarket數據的AI實驗性摘要。這不是交易建議,也不影響該市場的結算方式。 · 更新於Kyle Diamantas 67%
No announcement by December 31 16.3%
Stephen Hahn 7%
Brett Giroir 3.6%
Kyle Diamantas
52%
Stephen Hahn
7%
Brett Giroir
4%
Grace Graham
3%
Sara Brenner
3%
No announcement by December 31
16%
Kyle Diamantas 67%
No announcement by December 31 16.3%
Stephen Hahn 7%
Brett Giroir 3.6%
Kyle Diamantas
52%
Stephen Hahn
7%
Brett Giroir
4%
Grace Graham
3%
Sara Brenner
3%
No announcement by December 31
16%
An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs.
Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner.
Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify.
A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate.
If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”.
The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.
市場開放時間: May 12, 2026, 7:59 PM ET
Resolver
0x69c47De9D...An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs.
Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner.
Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify.
A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate.
If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”.
The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.
Resolver
0x69c47De9D...Recent developments in the Trump administration, including the resignation of FDA Commissioner Marty Makary, have elevated Deputy Commissioner for Food Kyle Diamantas to acting commissioner, positioning him as the leading candidate in trader assessments for a formal announcement. His prior role overseeing the Human Foods Program and connections within the administration contribute to the market's implied probability favoring his selection for the permanent post. Other potential nominees, including former officials and policy figures, trail significantly, reflecting limited recent signals of alternative appointments. The low odds on no announcement by year-end underscore expectations of a timely decision amid ongoing agency leadership transitions and policy priorities.
基於Polymarket數據的AI實驗性摘要。這不是交易建議,也不影響該市場的結算方式。 · 更新於
警惕外部連結哦。
警惕外部連結哦。
Frequently Asked Questions